Novavax Slips To Loss In Q2 On Reduced Revenue, Cuts FY26 Guidance

Novavax reported a Q2 slip to loss driven by lower total revenue year over year, and it also lowered its fiscal 2026 guidance. The combined earnings deterioration and guidance cut signal continued weakness in the company’s operating outlook. Expect NVAX to face downward pressure as markets reprice forward expectations.

Analysis

Novavax reported a Q2 slip to loss driven by lower total revenue year over year, and it also lowered its fiscal 2026 guidance. The combined earnings deterioration and guidance cut signal continued weakness in the company’s operating outlook. Expect NVAX to face downward pressure as markets reprice forward expectations.